Recently Featured

Lonza to Add Commercial Spray-Drying Capacity at Oregon Manufacturing Site

September 28, 2026
Lonza has announced plans to expand its US-based capacity for spray-dried dispersions by constructing two new PSD-4 units at its Bend, Oregon facility. This move comes as drug developers increasingly encounter formulation and bioavailability challenges associated with poorly soluble compounds. The demand for contract development and manufacturing services in this area has surged, necessitating enhanced…

Pharmaceutical Freebies Persist Despite Scrutiny, Influencing Physician Behavior

September 27, 2026
For years, drugmakers have offered free meals, samples, gifts, and speaking fees to physicians, a practice that raises concerns about potential biases in prescribing habits. This longstanding issue has been the subject of extensive research, reflecting a growing awareness of the ethical implications involved. Recent analysis sheds light on how these interactions have evolved over…

FDA Places Partial Hold on Biohaven’s Epilepsy Drug Opakalim

September 27, 2026
In a significant regulatory development, the FDA has placed a partial hold on Biohaven’s epilepsy drug, opakalim. This decision comes shortly after Biohaven divested the rights to the therapy, raising questions about the future of the drug’s clinical development. The hold specifically impacts a pivotal study that some analysts consider essential for securing potential approval…

Andy Plump, architect of Takeda’s R&D overhaul, to retire next year

September 27, 2026
Andy Plump, the President of Research and Development at Takeda Pharmaceuticals, is set to retire next year, marking the end of an era for the company. Plump joined Takeda during a turbulent period and has been instrumental in reshaping its R&D strategy, emphasizing collaboration with innovative biotech firms. Under his leadership, Takeda has established a…

Ongoing Cases